학술논문
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Document Type
Article
Author
Shitara, Kohei; Lordick, Florian; Bang, Yung-Jue; Enzinger, Peter; Ilson, David; Shah, Manish A; Van Cutsem, Eric; Xu, Rui-Hua; Aprile, Giuseppe; Xu, Jianming; Chao, Joseph; Pazo-Cid, Roberto; Kang, Yoon-Koo; Yang, Jianning; Moran, Diarmuid; Bhattacharya, Pranob; Arozullah, Ahsan; Park, Jung Wook; Oh, Mok; Ajani, Jaffer A
Source
In The Lancet 20-26 May 2023 401(10389):1655-1668
Subject
Language
ISSN
0140-6736